Filing Flows › Aytu Biopharma (AYTU) › Q4 FY25
Aytu Biopharma (AYTU) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Sep 23, 2025
Aytu Biopharma (AYTU) reported revenue of $15.1M for the fourth quarter fiscal 2025 (Q4 FY25), +4% from a year earlier and -18% from the quarter before. Operating margin was -50.4%, net loss $19.8M (130.9% of revenue).
Aytu Biopharma, Q4 FY25: revenue $15.1M (+4% year over year), operating margin -50.4%, net loss $19.8M, operating cash flow $2.8M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.1M | -18% | +4% |
| Operating profit | −$7.6M | -415% | — |
| Net earnings | −$19.8M | -596% | — |
| Operating cash flow | $2.8M | — | — |
| Free cash flow | $2.8M | — | — |
What changed
Revenue was $15.1M in Q4 FY25, up 4% year over year and down 18% from the previous quarter.
Gross margin was 67.8%, down 8.0 points from a year earlier. Operating costs exceeded revenue by $7.6M, an operating margin of -50.4%. Operating expenses grew 34% against revenue growth of 4%. The fastest-growing cost line was Other operating costs (+224%). The quarter ended with a net loss of $19.8M, after a profit of $4.0M the previous quarter. Net interest and other expense of $11.8M was the main reason.
Operating cash flow was $2.8M. Non-cash charges added back $1.5M of depreciation and amortization and $113K of share-based compensation. Working capital and other items added $21.0M. Capital expenditures of $17K left free cash flow of $2.8M.
Questions
What was Aytu Biopharma's revenue in the fourth quarter fiscal 2025?
Aytu Biopharma (AYTU) reported revenue of $15.1M for the fourth quarter fiscal 2025 (Q4 FY25), +4% from a year earlier and -18% from the quarter before.
Was Aytu Biopharma profitable in the fourth quarter fiscal 2025?
Operating loss was $7.6M (-50.4% of revenue) and net loss $19.8M.
Source: Aytu Biopharma 10-K on SEC EDGAR.